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Abstract 
 
 
 
COMPARISON OF ORAL KETAMINE-MIDAZOLAM AND CHLORAL HYDRATE-
MEPERIDINE-HYDROXYZINE SEDATION REGIMENS IN PEDIATRIC DENTISTRY 
 
By David W. Merrell, D.D.S. 
 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science 
in Dentistry at Virginia Commonwealth University 
 
Virginia Commonwealth University, 2013 
 
Director: Malinda M. Husson, D.D.S., M.S.D. 
Assistant Professor, Department of Pediatric Dentistry 
 
Purpose:  The purpose of this study was to create an experimental design to compare the 
regimen of ketamine-midazolam to chloral hydrate-meperidine-hydroxyzine for moderate oral 
conscious sedation.  
Methods: Patients between 36 and 83 months of age have been randomly assigned to receive 1 
of the 2 regimens. Dosages, times, and vital signs will be recorded. Procedures will be recorded 
on video for assessment of sedation level and behavior. Patients will be contacted to evaluate 
postoperative sleeping, discomfort, and amnesia. Data will be analyzed using two-group t-tests 
(TOST) of equivalence in means to compare the two groups across the study period. 
Results:  Patient enrollment of the study has begun. In order not to break the blind randomized 
code, future data analysis is pending final data collection.  
  
Conclusions: This study will assist clinicians by establishing if a regimen of ketamine-
midazolam is a comparable alternative to a regimen of chloral hydrate-meperidine-hydroxyzine 
for sedations.   
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Introduction 
 
 
 
Oral medications for minimal and moderate sedation of young, uncooperative dental patients are 
common, largely because drugs can easily and conveniently be administered via this route by the 
practitioner. The oral route is also economical in that no additional equipment is needed other 
than that required for monitoring.1 Oral medications are easily accepted by patients and parents 
due to ease of administration. If therapeutic doses are calculated for each individual patient, the 
oral route of sedation is relatively safe. 
Many drugs can be used for sedation, alone or in combination. The most commonly used 
medications are the benzodiazepines (ex. midazolam), chloral hydrate, meperidine, and 
hydroxyzine. The physiological and behavioral effects of these drugs are well documented.2-6 For 
a patient with moderate to severe anxiety, a single medication given at therapeutic dosage may 
not be sufficient. Clinicians may choose to use drug combinations, or “cocktails”, to take 
advantage of different drug properties. For example, a sedative can be combined with an 
analgesic (such as an opioid) to provide both anxiolysis and pain control.7 An anti-emetic can be 
given to offset nausea caused by certain drugs. However, if drug combinations are used or if 2 
routes are combined, the chance of an adverse side effect increases.  
Practitioners considering sedation must be very knowledgeable about the medications they 
intend to use and they must have the skills to rescue the patient from a deeper level of sedation 
than intended. For example, if the desired level of sedation is moderate, the practitioner must be 
able to rescue the patient from deep sedation. Sedation guidelines for children have been 
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endorsed and published by the American Academy of Pediatric Dentistry and the American 
Academy of Pediatrics. The recognized levels of sedation are minimal, moderate, and deep.7-9 
Beyond deep sedation is general anesthesia, a drug-induced loss of consciousness. Minimal 
sedation (formerly termed “anxiolysis”) is a drug-induced state where patients respond normally 
to verbal commands. Ventilatory and cardiovascular functions are unaffected. An example of 
minimal sedation is the use of nitrous oxide to assist a slightly anxious patient in a routine dental 
setting. With moderate sedation (formerly termed “conscious sedation” or “sedation/analgesia”), 
patients respond purposefully to verbal commands either alone or accompanied by light tactile 
stimulation (light tap, not a sternal rub). Reflex withdrawal, a normal response to pain, must be 
accompanied by another response such as pushing away the stimulus as to confirm higher 
cognitive function. Spontaneous ventilation is adequate and cardiovascular function is usually 
maintained. Deep sedation (formerly termed “deep sedation/analgesia”) describes a level of 
consciousness where patients cannot be easily aroused but respond purposefully after repeated 
verbal or painful stimulation. Independent ventilatory function may be impaired and protective 
airway reflexes may be lost. Cardiovascular function is usually maintained.8 Our intention is to 
achieve a level of moderate sedation for the patients included in this study. 
Nitrous oxide is often used as an adjunct to other sedatives to assist with anxiolysis, 
sedation, and analgesia. Nitrous oxide is an inhalation sedative shown to be safe and effective 
when used by a well-trained clinician. In addition to providing mild anxiolysis, nitrous oxide 
helps create a psychologically receptive mindset for the child patient and it complements oral 
sedatives by acting as a titrating and settling agent. During initiation of a procedure under 
sedation, nitrous oxide is often used in high concentration (50-70%) to settle the patient. Once 
the patient calms, it is usually reduced to below 50% for the duration of the procedure.7 
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Chloral Hydrate 
One of these medications, chloral hydrate, is a sedative hypnotic with a long history of 
relative safety. Chloral hydrate is often selected for sedations involving more lengthy dental 
procedures. This is due in part to its elimination half-life of 8-11 hours. In therapeutic doses 
chloral hydrate has minimal cardiovascular or respiratory effect, has an onset of 30 to 60 
minutes, peak of 60 minutes, and duration of 4-8 hours. Chloral hydrate is metabolized to 
trichloroethanol (TCE) in the liver and is excreted by the kidneys. Undesirable aspects of the 
drug are lack of a reversal agent, gastric irritation, and an unpleasant taste. Chloral hydrate is 
often combined with other medications such as meperidine and hydroxyzine to enhance level of 
sedation and offset certain side effects, such as gastric irritation.  
Recommended therapeutic dosing of chloral hydrate for sedative procedures ranges from 25-
100 mg/kg for children although doses more than 75 mg/kg have been shown to cause central 
nervous system instability.10 One study concluded that doses of 40 mg/kg or less had no more 
effect than placebo. This same study concluded that 60 mg/kg was required to improve 
behavior.11 A combination of chloral hydrate 40 mg/kg, meperidine 0.5 mg/kg, hydroxyzine 25 
mg, and 50% nitrous oxide resulted in 85% good (some difficulty, but all treatment performed) 
or better behaviors according to another study.5 Yet another study deemed a combination of 
chloral hydrate 55 mg/kg, and hydroxyzine 1 mg/kg to be just under 74% effective.4 Differences 
in research methods and differences in defining what constitutes an effective sedation make 
comparing results difficult.12 A regimen of chloral hydrate (Gallipot®, Inc.) 35 mg/kg, 
meperidine (Demerol®) 1.5 mg/kg, and hydroxyzine (Vistaril®) 1.5 mg/kg was chosen for this 
study based on a history of successful sedations within the Virginia Commonwealth University 
Pediatric Dentistry clinic. In this triple “cocktail”, chloral hydrate acts as the sedative agent, 
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meperidine is added as a narcotic pain reliever, and hydroxyzine is added to counteract the side 
effect of gastric irritation and nausea caused by the chloral hydrate. Hydroxyzine also acts as a 
mild sedative. 
Chloral hydrate oral solution had been available in 16 full oz. retail packages and 5 mL unit 
dose packages that were convenient for record keeping in multi-doctor settings such as residency 
programs. However, in May 2012 manufacture of chloral hydrate oral solution was discontinued. 
Chloral hydrate is still available in crystal form, but the dentist or participating pharmacy must 
compound the drug into oral solution. Prior to securing a pharmacy that would compound chloral 
hydrate into oral solution, VCU Pediatric Dentistry looked at alternative medications that might 
work well for oral conscious sedations involving lengthy dental procedures. Oral ketamine 
seemed promising and was used successfully, in conjunction with oral midazolam, for a number 
of oral sedations in the VCU Pediatric Dentistry clinic. A literature review evaluating the use of 
oral ketamine with other medications and a review of equivalence studies were completed and 
reviewed prior to further consideration. 
 
Ketamine 
Ketamine is a dissociative anesthetic that has been shown to be a safe and effective oral 
sedative.13-19 Ketamine is a derivative of the hallucinogen phencyclidine.14,20 It has a fast onset, 
approximately 20 minutes, because of its high lipid solubility and quick entry into the 
CNS.13,15,16,18,21,22 Working time is adequate at around 36 minutes.23 Oral ketamine produces 
sedation, analgesia, maintains the protective airway reflex, maintains or stimulates the 
cardiorespiratory system, and has a wide safety margin.13,14,24-26 
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Dissociative sedation describes a state of consciousness where the patient feels disconnected 
or unaware of his or her surroundings. Nystagmus, or the vacant, glassy-eyed “ketamine stare” 
marks the onset of this state. Patients may experience nonpurposeful movement independent of 
verbal or painful stimulation but are still able to independently maintain their own protective 
reflexes.13,14,27 This cataleptic state is caused by dissociation between the thalamoneocortical and 
limbic systems. This dissociation prevents the higher brain centers from perceiving visual, 
auditory, or painful stimuli.13,28 Ketamine binds to N-methyl-D-aspartate (NMDA) receptors in 
the CNS, a subgroup of sigma opioid receptors. This causes ketamine’s analgesic effect.29 
Termination comes about due to redistribution to the peripheral compartment. Ketamine is also 
metabolized by the cytochrome P450 system to norketamine, an active metabolite, which has 
one-third the potency of ketamine itself.14 
Ketamine enhances upper airway muscular tone and preserves spontaneous respiration.13,14 
Bronchodilation and decreased airway resistance due to inhibition of vagal outflow, increased 
circulating catecholamines, and smooth muscle relaxation, may lead to increases in O2 
saturation. However, ketamine stimulates salivary and airway secretions increasing the risk of 
laryngospasm. This can be controlled by concomitant use of an antisialogogue. Ketamine has a 
mild to moderate stimulatory effect on the cardiovascular system. The sympathomimetic effects 
are due to the inhibition of catecholamine reuptake at adrenergic nerve terminals. Increased 
myocardial O2 consumption causes an increase in coronary perfusion. Therefore, ketamine is 
relatively contraindicated in patients with heart disease or uncontrolled hypertension. Other side 
effects include skeletal muscle rigidity and hyper tonicity.14 Random movements unrelated to 
stimuli have been mistaken for seizure activity although ketamine has been shown to not alter the 
seizure threshold in epileptics. Ketamine even possesses anticonvulsive properties. Ketamine has 
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been shown to elevate intracranial pressure due to increased cerebral blood flow. Therefore, 
ketamine is also relatively contraindicated in patients with hydrocephalus or intracranial lesions 
since apnea, ataxia, or dizziness may persist for up to 4 hours after ketamine administration. 
Reports indicate that 0-10% of children experience hallucinogenic reactions such as strange 
dreams, feelings of detachment, or out of body experiences. Risk for hallucinogenic reactions 
increases for patients over 10 years of age, of female gender, and having a history of personality 
disorders; hallucinogenic reactions may be experienced if patients are excessively stimulated 
during recovery. Concomitant use of benzodiazepines, opioids, or propofol may attenuate these 
reactions.13,14 0-43% of adults and 0-10% of children also experience nausea and vomiting upon 
emergence from sedation. This usually happens in the late recovery phase when the patient is 
alert.13-16,23,26 Post-operatively, children have been reported to sleep at home for up to 6 hours; 
one study reported an average of 3 hours.13,15 
Literature reports oral ketamine dosages ranging from 3-10 mg/kg with varying success 
rates.13,15-19,26 A regimen of 3 mg/kg oral ketamine with 0.4 mg/kg midazolam was chosen for 
this study. Earlier trial sedations at VCU Pediatric Dentistry using 4 or 5 mg/kg ketamine with 
0.5 mg/kg midazolam resulted in longer recovery times than desired. As mentioned previously, 
midazolam (a benzodiazepine) is being used in this study to help offset possible ketamine-
induced hallucinogenic reactions during emergence from sedation. Benzodiazepines also 
contribute to sedative drug combinations with their sedative, anxiolytic, amnestic, hypnotic, and 
anticonvulsive properties.7 
The goal of this study is to answer if a regimen of ketamine-midazolam (K-M) is as 
effective or more effective than a regimen of chloral hydrate-meperidine-hydroxyzine (CH-D-H) 
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for oral conscious sedations. This study also attempts to compare recovery times, postoperative 
sleeping, discomfort, and amnesia involved with use of the two regimens. 
 
Methods 
Subject Selection  
In order to properly determine the number of subjects necessary to determine equivalence, a 
power calculation was completed. The VCU Human Subjects IRB approved the study prior to 
starting (# HM14735). An experimental design was developed to determine equivalence utilizing 
the programs nQuery Advisor + nTerim® (Statistical Solutions, Saugus, MA) and SAS software 
(SAS Institute Inc., Cary, NC). Residents of the Virginia Commonwealth University Pediatric 
Dentistry residency program will perform 50 oral conscious sedations. Patients included in the 
study will have been previously selected for sedation and will range in age between 36-83 
months. Other inclusion criteria include a history of fearful or refractory behavior at previous 
dental appointments as documented by Frankl behavior rating scores of 1 or 2. Patients to be 
included must have a classification of ASA 1 and less than 50 percent tonsillar obstruction 
(rating of Brodsky 1 or 2). Brodsky rating is a standardized tonsillar hypertrophy grading scale 
(0= tonsils are entirely within the tonsillar fossa, 1= tonsils occupy less than 25% of the lateral 
dimension of the oropharynx as measured between the anterior tonsillar pillars, 2= less than 
50%, 3= less than 75%, 4= 75% or more). Patients will be required to obtain a history and 
physical from their primary care physician to determine if the patient is healthy and well for 
dental treatment under moderate oral conscious sedation. All patients will have an NPO (nil per 
os, Latin for “nothing through the mouth”) status of more than 8 hours prior to sedation.  
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Procedure 
Patients will be moderately sedated using 1 of 2 oral drug regimens: a combination of 
ketamine (Ketalar® – JHP Pharmaceuticals, Parsippany, NJ) 3 mg/kg and midazolam (Hospira, 
Inc., Lake Forest, IL) 0.4 mg/kg (K-M) or a triple combination of chloral hydrate (Chloral 
Hydrate Crystal USP – Gallipot/Fagron, St. Paul, MN) 35 mg/kg (1g maximum), meperidine 
(Demerol® – Winthrop/Breon, New York, NY) 1.5 mg/kg, and hydroxyzine (Vistaril® – Pfizer, 
New York, NY) 1.5 mg/kg (CH-D-H).  
Children from both groups will receive between 30-50% nitrous oxide during treatment. 
Twenty-five patients in the study have been randomly assigned to receive the (K-M) 
combination and 25 have been randomly assigned to receive the (CH-D-H) combination using 
SAS software (SAS Institute Inc., Cary, NC). A description of the assigned regimen will be 
concealed in a folder labeled with the patient number and will be revealed to the operator just 
prior to drug administration.  
Each procedure will be video recorded on a DVD (Sony DCR-DVD308 Handycam®, Sony 
Electronics Inc., San Diego, CA) labeled with the assigned patient number and date. Sedation 
visits will involve these common procedures after patients are brought to the operatory: Video 
recording, review of informed consents including consent for the study, review of the history and 
physical form, review of the medical history and review of systems update (to ensure no changes 
in health), confirmation of NPO status, airway assessment to evaluate Brodsky score (tonsillar 
tissues), and baseline vital signs (heart rate, SpO2, and blood pressure). If patients are assessed as 
being healthy for the procedures, oral medications will be administered via a cup or oral syringe. 
The patients will be observed in the dental chair for 20 minutes (for K-M sedations) or 60 
minutes (for CH-D-H sedations) with a parent present. Patients will be placed on a Papoose 
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Board® (Olympic Medical Corp., Seattle, WA) and left unsecured, partially secured, or fully 
secured for protective stabilization depending on the operator’s discretion. The parents will be 
escorted to the reception area. Patients will initially receive 100% O2 for 2-5 minutes, then will 
be given an inhalation mixture ranging from 30-50% N2O via a nitrous hood over the nose prior 
to initiating the dental procedure. Dental procedures will include the use of a mouth prop, rubber 
dam, or IsodryTi (Isolite Systems, Santa Barbara, CA). 
The following will be recorded before, during, or after the procedure by an assigned 
monitor: patient number, age, weight, indication for sedation, ASA classification, pre-operative 
medication dosages and times, nitrous oxide dosage and times, local anesthesia dosage and 
times, procedure times (start to finish), recovery time (end of procedure to discharge), O2 
saturation, blood pressure, and heart rate. Vital signs will be taken every 5 minutes (Appendix 1).  
 
Behavior and Sedation Level Evaluation 
Two pediatric dentists, who are not operators in the study, will independently watch the 
recorded procedures and assess protective stabilization (no wrap, partial wrap, full wrap), 
sedation level, and behavior (amount of sleep, body movement, head/oral resistance, crying, 
verbal responsiveness, followed by an overall sedation rating) (Table 1). Both dentists will be 
blind to the sedation regimens given. Sedation level and behavior will be recorded at the 
following times: 1) medication administration, 2) entrance of the operator into the treatment 
room, 3) local anesthetic administration, 4) procedure start, 5) every 10 minutes until 6) 
procedure stop (Appendix 2). The behavior rating criteria is similar to the criteria used by 
Reinemer et al (1996),15 a modified version of the scale developed by Houpt et al (1985).5,30 To 
establish reliability and permit rater training, 10 DVD behavior and sedation level evaluations  
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Table 1.    BEHAVIOR AND SEDATION LEVEL 
 
 
 
will be selected to calibrate examiners. We expect the kappa statistic for inter-examiner 
reliability to be between 0.7 and 0.9. 
Criteria for discharge will include the following: satisfactory and stable cardiovascular 
function, airway patency, easy arousability, responsiveness near presedation levels, intact 
protective reflexes, ability to talk, ability to sit up unaided, and adequate state of hydration. 
Patients will be released to the care of their guardians after they meet these discharge criteria. 
The guardians will be given written and verbal post-operative care instructions and a copy of the 
Wong-Baker FACES Pain Rating Scale31 (Figure 1) for reference during the post-op phone call.  
Patients will then be transported to their cars in a wheelchair. Patients will be called 
approximately 7 hours following the procedure to evaluate postoperative sleeping, discomfort, 
and amnesia (Appendix 3). 
 
 
 
PAPOOSE 
1. No wrap 
2. Partial wrap 
3. Complete wrap 
 
 
SLEEP 
1. Awake, alert 
2. Drowsy, disoriented 
3. Intermittently asleep 
4. Sound asleep 
 
BODY MOVEMENT 
1. Violent, interrupting treatment 
2. Continuous, making treatment difficult 
3. Controllable, does not interfere with treatment 
4. No body movement present 
 
HEAD/ORAL RESISTANCE 
1. Turns head, refuses to open mouth 
2. Mouth closing, must request to open 
3. Choking, gagging, spitting 
4. No head/oral resistance present 
 
CRYING 
1. Hysterical, demands attention 
2. Continuous, making treatment difficult 
3. Intermittent, mild, does not interfere 
4. No crying present 
 
VERBAL 
1. Verbal abuse, threats 
2. Verbal protest 
3. Statement of discomfort 
4. Occasional talking or silence 
 
OVERALL 
1. Aborted – no treatment performed 
2. Very poor – Tx interrupted, partial treatment 
completed 
3. Poor – Tx interrupted, all treatment completed 
4. Fair – difficult, all treatment performed 
5. Good – some limited crying or movement 
6. Excellent – no crying or movement 
 
 
 
SEDATION LEVEL 
1. None 
2. Minimal 
3. Moderate 
4. Deep 
5. General Anesthesia 
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Data Analysis  
Data will be collected for numerous variables. However, the primary variable to be 
analyzed will be the overall sedation score. Patients were randomly assigned to a group, n=25 
per group. It is thought that if the 2 overall sedation behavior scores have a difference of 0.1  
(SD = 1.5 per group), then the study has 75% power to claim equivalence to within ±1.25 units 
(Figure 2). We feel that 75% power is enough to claim that the 2 regimens are equivalent. Data 
will be analyzed using two-group t-tests (TOST) of equivalence in means to compare the 2 
groups across the study period. 
 
Figure 1.  Pain rating scale recommended for children 3 years and older developed by Donna Wong and Connie Baker 
Figure 2. Equivalence Study Design Analysis 
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Results 
Patient enrollment of the study has just begun. In order not to break the blind randomized 
code, future data analysis is pending final data collection. We will continue the study and post 
results in the near future. 
 
Discussion 
Unlike most randomized controlled trials, equivalence trials do not try to determine if one 
intervention is superior to another. The goal of an equivalence trial is to show that there are no 
significant differences between 2 or more treatments.32 Typically a new intervention is compared 
to an existing treatment (active control).33 Investigators must determine how much difference can 
be tolerated as clinically irrelevant. Relevant differences must be stated in the protocol.32 For this 
study, the primary outcome to be analyzed will be the (overall) behavior and sedation score 
(Table 1). Based on experience, it is expected that the CH-D-H sedations will have a mean of 4 
(Fair – difficult, all treatment performed). It is our expectation that the K-M sedations will have a 
very similar, possibly higher mean, expected to be around 4.1 (Figure 2). Our power analysis, 
using these numbers, determined we would need a minimum of 50 study participants. These 
expected means differ from some found in the literature. Poorman et al5 found an overall 
behavior rating mean of 5 (Table 1) with CH-D-H regimens. Reinemer et al15 found an overall 
behavior rating mean of 3.1 when using 4 mg/kg of ketamine for sedations. A power analysis 
comparing these very different means would have required a minimum of 700 patients, a number 
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not feasible for a 2-year residency program. We attribute these different means to differences in 
study design and methods as mentioned previously. 
One limitation of the study is the multi-doctor setting in which the sedations will take 
place. Ten residents will be acting as operators in the sedations and each comes with a varying 
level of experience and each has his or her own style of behavior management. These differences 
could impact patient behavior during the sedations. In addition, resident interpretation of pre-
sedation behavior (Frankl rating) at work-up appointments could vary potentially affecting who 
is and who is not included in the study. Residents might also vary on determination of when a 
patient has met discharge criteria affecting calculated recovery times. 
Another limitation of the study might be the strictness of the inclusion and exclusion 
criteria. The majority of patients undergoing sedation at VCU do not meet inclusion criteria. The 
study design calls for only patients rated as ASA I to be included. This was done in effort to omit 
some potentially complicating variables such as illnesses and medication interactions. However, 
many patients undergoing sedation at VCU Pediatric Dentistry have an ASA II rating due to 
health histories that include such diagnoses as asthma, eczema, ADHD, etc. Additionally, the 
study design only includes patients with behavior rated as Frankl 1 or 2 in an effort to ensure all 
study participants have similar dispositions (negative behavior). Numerous patients who will 
undergo sedation at VCU will be excluded because they will be rated as having Frankl 3 
behavior (somewhat cooperative), and will be sedated to assist with mild anxiety not controllable 
with nitrous oxide alone. With the majority of patients being sedated not meeting inclusion 
criteria, the study could potentially extend for a great length of time in order to include all 50 
needed participants. Discussion about alteration of inclusion criteria for our study model is 
continuing. It has also been suggested that the study may benefit from including intraoperative 
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complications such as laryngospasms, excessive salivation, respiratory depression, nausea, or 
vomiting. 
If our experimental design was developed correctly, the statistical analysis will show that 
the regimen of ketamine-midazolam is equivalent to chloral hydrate-meperidine-hydroxyzine. 
Most children can achieve dental care in a routine setting. Some children require an advanced 
behavioral management technique, including pharmacological management, for the completion 
of dental treatment. We continue to strive to find a safe alternative to the use of CH.   
 
Conclusions: 
This study will assist clinicians by establishing if a regimen of ketamine-midazolam is an 
equivalent alternative to a regimen of chloral hydrate-meperidine-hydroxyzine for oral conscious 
sedations.  
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PATIENT'#'________''' ' ' ' ' ' ' '''''''''''' '''''''''''''CLINICAL'MONITORING'–'ATTACHMENT'A'
'
Comparison*of*oral*ketamine0midazolam*and*chloral*hydrate0meperidine0hydroxyzine*sedation*regimens*in*pediatric*dentistry**
'
Age'________'mos' Procedure'Time'1=2'_________'min' Chloral'Hydrate'(35mg/kg)'_______mg' Ketamine'(3mg/kg)'''''''''_______mg'
Weight''_____kg' Recovery'Time'2=3'''_________'min' Meperidine''(1.5'mg/kg)'''''_______mg' Midazolam'(0.4'mg/kg)''_______mg'
' ' ' Hydroxyzine'(1.5'mg/kg)'''''_______mg'
'
Nitrous'Oxide''30–50%' ''''''''''''''''''''''''''''''''''''''''''''Record'vital'signs'every'5'minutes.''Use'an'“X”'to'document'times'for'each'part'of'procedure.'
'
TIME* Base' :' :' :' :' :' :' :' :' :' :' :' :' :' :' :' :'
Drug*Admin* ' X' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
Enter*Operator* ' ' X' ' ' ' ' ' ' ' ' ' ' ' ' ' '
Local*Anesthesia** ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
SpO2* ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
Pulse* ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
BP* /' /' /' /' /' /' /' /' /' /' /' /' /' /' /' /' /'
Procedure*Start1* ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
Procedure*Stop2* ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
Discharge*3* ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
'
'
Continue'here'if'necessary'
'
TIME* :' :' :' :' :' :' :' :' :' :' :' :' :' :' :' :' :'
Drug*Admin* ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
Enter*Operator* ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
Local*Anesthesia** ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
SpO2* ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
Pulse* ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
BP* /' /' /' /' /' /' /' /' /' /' /' /' /' /' /' /' /'
Procedure*Start1* ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
Procedure*Stop2* ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
Discharge*3* ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
'
'
'
'
'
'
'
'
'
'
'
'
'
'
'
'
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Appendix 1 
Clinical Monitoring Data Collection Sheet 
 
 
 
 
 
 
 
 
 
 
 
 
  22 
 
 
 
Appendix 2 
Video Monitoring Data Collection Sheet 
 
 
 
 
 
 
 
 
 
 
 
 
PATIENT'#'________'''''''EVALUATOR'___________________'' ' ' ' ''''''''''''''''''VIDEO'MONITORING'–'ATTACHMENT'B'
'
Comparison*of*oral*ketamine0midazolam*and*chloral*hydrate0meperidine0hydroxyzine*sedation*regimens*in*pediatric*dentistry*'
'
'
'
'
TIME'
Papoose'
Board'
Sedation'
Level'
BEHAVIOR'
' Sleep'
Body'
Movement'
Head/Oral'
Resistance' Crying' Verbal' Overall'
Drug'Administration' :' ' ' ' ' ' ' '
'
Entrance'Operator' :' ' ' ' ' ' ' '
Local'Anesthesia'' :' ' ' ' ' ' ' '
Procedure'Start1' :' ' ' ' ' ' ' '
10'min' :' ' ' ' ' ' ' '
10'min' :' ' ' ' ' ' ' '
10'min' :' ' ' ' ' ' ' '
10'min' :' ' ' ' ' ' ' '
10'min' :' ' ' ' ' ' ' '
10'min' :' ' ' ' ' ' ' '
10'min' :' ' ' ' ' ' ' '
10'min' :' ' ' ' ' ' ' '
10'min' :' ' ' ' ' ' ' '
Procedure'Stop2' :' ' ' ' ' ' ' ' '
'
'
'
PAPOOSE*
1. No'wrap'
2. Partial'wrap'
3. Complete'wrap'
*
*
SLEEP*
5. Awake,'alert'
6. Drowsy,'disoriented'
7. Intermittently'asleep'
8. Sound'asleep'
'
BODY*MOVEMENT*
1. Violent,'interrupting'treatment'
2. Continuous,'making'treatment'difficult'
3. Controllable,'does'not'interfere'with'treatment'
4. No'body'movement'present'
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
9/26/12'
HEAD/ORAL*RESISTANCE*
1. Turns'head,'refuses'to'open'mouth'
2. Mouth'closing,'must'request'to'open'
3. Choking,'gagging,'spitting'
4. No'head/oral'resistance'present'
*
CRYING*
1. Hysterical,'demands'attention'
2. Continuous,'making'treatment'difficult'
3. Intermittent,'mild,'does'not'interfere'
4. No'crying'present'
'
VERBAL*
1. Verbal'abuse,'threats'
2. Verbal'protest'
3. Statement'of'discomfort'
4. Occasional'talking'or'silence'
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
OVERALL*
1. Aborted'–'no'treatment'performed'
2. Very'poor'–'Tx'interrupted,'partial'treatment'
completed'
3. Poor'–'Tx'interrupted,'all'treatment'completed'
4. Fair'–'difficult,'all'treatment'performed'
5. Good'–'some'limited'crying'or'movement'
6. Excellent'–'no'crying'or'movement'
*
*
*
SEDATION*LEVEL*
1. None'
2. Minimal'
3. Moderate'
4. Deep'
5. General'Anesthesia'
'
'
'
'
'
'
'
'
'
'
'
'
'
'
'
'
'
' ' ' ''''''''''Page'1'of'1
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Appendix 3 
Follow-Up Data Collection Sheet 
 
 
 
 
 
 
 
 
 
 
 
 
'PATIENT'#'________'''''''' ' ' '' ' '''''''''''''''' ' ' ' '''''4=6'HOUR'FOLLOW=UP'PHONE'CALL'
'
Comparison*of*oral*ketamine0midazolam*and*chloral*hydrate0meperidine0hydroxyzine*sedation*regimens*in*pediatric*dentistry*
*
POST0OPERATIVE*SLEEPING'
1. None'(Awake,'alert)'
2. Drowsy,'disoriented'
3. Intermittent'sleep'
4. Sound'asleep'
'
SLEEP*DURATION*(if'applicable)'
1. Less'than'1'hour'
2. 1=3'hours'
3. 4=6'hours'
4. 7'or'more'hours'
'
DISCOMFORT'
'
PAIN*MEDS*REQUIRED'
1. Yes' ''''If'yes,'what'given'(ex.'Ibuprofen,'Tylenol,'etc)'_________________________'
2. No'
*
AMNESIA'
1. Entire'procedure'remembered'
2. Most'of'procedure'remembered'
3. Little'of'procedure'remembered'
4. Nothing'of'procedure'remembered'
'
COMPLICATIONS*(circle'if'any)'
1. Psychic'phenomena'/'nightmares'
2. Headache'
3. Nausea/vomiting'
4. Skin'rash'
'
'
'
'
'
'
'
'
9/26/12' ' ' ' ' ' ' ' ' ' ' ' ' ' '''''''''''''''''''Page'2'of'2'
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